Limb-sparing treatment for canine osteosarcoma to be explored in new studyNovember 14, 2023The new research is set to evaluate the effectiveness of a novel drug combination tailored to giant-breed dogs diagnosed with osteosarcoma.
SPONSORED CONTENTOne dose protects for 12 months.One ProHeart® 12 (moxidectin) injection puts compliance in your control. + Get started
Limb-sparing options for osteosarcoma-diagnosed dogs to be exploredJuly 28, 2022The Morris Animal Foundation-funded project will investigate limb-sparing options for large- and giant-breed dogs diagnosed with osteosarcoma. Ultimately, researchers hope to advance the treatment of and improve the prognosis for dogs receiving radiation treatment for this type of cancer.
Technicians are tops: The changing role of this critical team memberOctober 12, 2020It’s National Veterinary Technician Week, a time when we honor these tireless professionals who have never been more critical to animal health than over the last eight months or so.
Osteosarcoma in dogs and children genetically similarJuly 26, 2019The veterinary community might soon see advancements in the treatment of canine osteosarcoma (OS).
Osteosarcoma: Beyond amputation and euthanasiaMarch 12, 2019When a patient is diagnosed with osteosarcoma, we tend to focus on three options: • the "gold standard," i.e. amputation with or without chemotherapy; • what many call palliative care, meaning pain medication and rest; or • euthanasia. But what if amputation is not an option? What if chemotherapy or radiation is out of the owner's financial capabilities? Or a couple of medications are not enough to numb the pain? What if visible metastasis to the lungs is already present? Bob Stein, DVM, pain management guru and founder of the Veterinary Anesthesia & Analgesia Support Group (www.vasg.org), recently shared another valid option.* "With my suggested approach, we can often provide quality of life to even large-breed dogs for six to 12 months and sometimes more than 20." Let's detail Dr. Stein's protocol. Pamidronate Pamidronate, a bisphosphonate, is an injectable drug that is inexpensive and easy to administer (ref: TM Fan et al. JVIM 2007). It helps to reduce pain (in 30 to 50 percent of patients), inhibit bone osteolysis, and has potential cancer-suppression effects by impeding proliferation and inducing apoptosis. The drug has a wide safety margin and can even be used on patients with renal or …
The race to develop immunotherapies for canine lymphoma and osteosarcomaJanuary 2, 2019There are many reasons why development of immunotherapies in dogs has been slow. Although cancer, and in particular lymphoma and osteosarcoma, is frequent in dogs, just one percent of owners have pet insurance; those who don’t are willing to spend only a limited amount of money to treat their dog, especially when initial treatment results are not as dramatic as in humans.
20-plus clinics to participate in expanded osteosarcoma vaccine clinical trialSeptember 6, 2018Initial results of a pilot study for canine osteosarcoma vaccine are promising, prompting a larger study to test its safety and efficacy. Pharmaceutical company Aratana Therapeutics, which received conditional licensure for Live Listeria Vector (AT-014), has expanded its clinical trial to include more than two dozen veterinary oncology practice groups across the U.S. in order to receive full licensure. Conducted by the University of Pennsylvania School of Veterinary Medicine, the pilot study tested the immunotherapy treatment in 18 dogs. Those that received the vaccine lived more than twice as long as the historical, matched control group, with median survival times of 956 days compared to 423 days. The expanded clinical trial is designed to collect additional safety data for the vaccine in dogs that have undergone amputation of the affected limb and have already completed chemotherapy. If the treatment is found to be as safe and effective as it appeared in the initial clinical trial, Aratana will be given full licensure, allowing it to make the drug commercially available. Live Listeria Vector (AT-014) is created by removing harmful genes from the Listeria bacteria and then attaching markers of osteosarcoma cells. It is designed to supplement standard osteosarcoma treatment of amputation …
ELIAS presents preliminary canine osteosarcoma results at ACVIMAugust 3, 2018During the 2018 American College of Veterinary Internal Medicine Forum in June, ELIAS Animal Health, a clinical stage development company advancing novel treatments for companion animal cancer, shared preliminary canine osteosarcoma results for its cancer immunotherapy. According to study results presented by Brian Flesner, DVM, DACVIM (Oncology), University of Missouri, the company's new ELIAS autologous cancer vaccine, featuring a patented vaccine and T cell infusion combination approach, demonstrated "impressive survival times and minimal side effects." This cancer immunotherapeutic is being distributed as an experimental product under 9 CFR 103.3 to veterinarians treating dogs diagnosed with cancer. Efficacy and safety have not been established. One in four dogs will be impacted by cancer in their lifetimes, and cancer is the No. 1 cause of death in dogs older than 2. "There has been growing frustration in the veterinary profession with current treatment options, including chemotherapy and radiation, which have only modestly improved outcomes over the past 20 years," said Noe Reyes, DVM, medical director, ELIAS Animal Health. "We are very encouraged by the positive treatment outcomes reported by Dr. Flesner at ACVIM and look forward to starting our pivotal osteosarcoma trial evaluating this T cell-based immunotherapy in a broader population," …
Canadian researchers team up to fight canine osteosarcomaJune 14, 2018A group of researchers called the Dog Osteosarcoma Group–Biomarkers of Neoplasia (DOGBONe) at the University of Guelph in Ontario, Canada, have joined forces to determine more accurate ways of measuring bone cancer, with the main objective of identifying biomarkers to assess patients with canine osteosarcoma. The presentation of osteosarcoma in dogs is remarkably similar to that of humans, according to the Ontario Veterinary College (OVC); so much so that computers are unable to distinguish between tumor samples from each species based on gene expression patterns. These similarities make canine osteosarcoma research all the more valuable, as any progress in developing better treatments for one species means progress for the other as well. "The dogs are a model for the worst of the human disease," said Geoffrey A. Wood, DVM, Ph.D., DVSc (pathology), of the OVC's Department of Pathobiology. "Right now, the information we find out in human osteosarcoma serves as a model for the dogs. There's an opportunity to go both ways between the species, for the benefit of both." The team consists of the university's top osteosarcoma researchers from across four departments at OVC, including co-leaders Dr. Wood and Alicia Viloria-Petit, Ph.D., MSc, BSc, of the Department of …
MAF awards Penn $775K to test osteosarcoma immunotherapy vaccine in dogsApril 20, 2018Morris Animal Foundation (MAF) has awarded a $775,000 grant to the University of Pennsylvania to test a vaccine that could improve longevity and quality of life for dogs with osteosarcoma. The research team will conduct clinical trials to evaluate a novel immunotherapy treatment that combines a molecule expressed by cancer cells with a modified live form of Listeria monocytogenes. A pilot study demonstrated this combination elicited a powerful, targeted immune response directed against osteosarcoma cells in patients suffering from this type of cancer. "This could be an incredible breakthrough in the fight against osteosarcoma, a highly aggressive and deadly cancer," said Kelly Diehl, DVM, DACVIM (SAIM), senior scientific programs and communications adviser at MAF. "For the last 50 years, Morris Animal Foundation has been funding cancer studies, and this is one of the largest, single grants we have ever awarded. The results of the pilot study were so compelling, that we knew we had to support this research team and their progression to a clinical trial." The vaccine, created by removing harmful genes from the Listeria bacteria and then attaching markers of osteosarcoma cells, supplements standard osteosarcoma treatment of amputation and chemotherapy by attacking cancer cells that …
